Aurigene Pharmaceutical Services Enters Into Long-Term Manufacturing And Supply Partnership With A Leading Global Pharmaceutical Company

Aurigene Pharmaceutical Services Limited (“Aurigene”), a wholly owned subsidiary of Dr. Reddy's Laboratories Ltd., today announced a strategic, long-term Manufacturing and Supply Agreement (MSA) with a leading global pharmaceutical company for the commercial drug-product manufacturing and supply of a diversified portfolio for USA, Europe, Canada and Emerging markets.

The agreement establishes a full-service framework for technical transfer, process development, scale-up, validation, commercial manufacturing and long-term supply. The collaboration highlights Aurigene’s expanding drug product CDMO (Contract Development and Manufacturing Organization) and CMO (Contract Manufacturing Organization) capabilities, particularly in sterile injectables and biologics, complementing its established development and manufacturing expertise across the pharmaceutical value chain.

The initial portfolio comprises 20+ products spanning sterile injectables, biologics and topicals, to be manufactured across facilities in India. The partnership is expected to progress through a phased technology transfer program over the next two to three years, paving the way for commercial manufacturing and supply. At full commercialization, the portfolio is expected to represent an estimated annual volume of approx.18 million units, largely being injectables, with revenues expected to commence from the calendar year 2028.

“We are delighted to enter into this strategic, long-term collaboration,” said Akhil Ravi, Chief Executive Officer, Aurigene Pharmaceutical Services. “This partnership reflects the confidence global innovators place in our integrated drug-product development and manufacturing capabilities of sterile injectables, biologics and topicals, our proven quality and regulatory track record, and our ability to support complex technology transfers and commercial supply. It provides long-term revenue visibility, accelerates the scale-up of our drug-product business, and reinforces our commitment to reliable, high-quality supply to patients worldwide.

The counterparty's name has not been disclosed in view of confidentiality obligations under the agreement

About Aurigene Pharmaceutical Services Limited
Aurigene Pharmaceutical Services Limited, a subsidiary of Dr. Reddy’s Laboratories, is an integrated contract research, development and manufacturing organization (CRDMO) offering end-to-end drug-substance and drug-product services from discovery through development and commercial manufacturing for Small molecules, peptides, biologics and sterile injectables. For more information, visit www.aurigeneservices.com